Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
Eledon Pharmaceuticals (Nasdaq: ELDN) announced that CEO David-Alexandre C. Gros, M.D. will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT).
The session will be available via live webcast with a replay accessible on the company website under Events for registered attendees.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ELDN declined 6.13%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ELDN gained 8.97% while close peers showed mixed moves: AARD rose 8.4%, NVCT 2.57%, MCRB and NKTX were modestly positive, and CABA fell 2.88%. With no peers in the momentum scanner and no same-day peer headlines, today’s move appears more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Conference participation | Neutral | -6.1% | CEO fireside chat announcement at Piper Sandler conference. |
| Nov 18 | Clinical data update | Positive | -4.9% | Preliminary tegoprubart data in type 1 diabetes islet transplant trial. |
| Nov 14 | Earnings and pipeline | Neutral | -8.0% | Q3 2025 results, BESTOW Phase 2 data and financing update. |
| Nov 12 | Offering priced | Negative | -11.3% | Pricing of $50M underwritten offering with common stock and pre-funded warrants. |
| Nov 11 | Offering proposed | Negative | -5.3% | Proposed underwritten equity and pre-funded warrant offering announcement. |
Recent history shows negative reactions to both positive clinical/financial updates and dilutive offerings, with several news events followed by single-day declines.
Over the last month, ELDN has combined clinical progress, financing activity, and investor outreach. On Nov 11–12, 2025, it announced and priced an underwritten public offering with pre-funded warrants, followed by Q3 results and Phase 2 BESTOW data on Nov 14, all met with single-day share declines. Preliminary islet transplant results on Nov 18 likewise saw a negative reaction. Today’s Dec 1 conference participation notice continues a pattern of frequent news flow tied to clinical development and capital raising.
Market Pulse Summary
The stock moved -6.1% in the session following this news. A negative reaction despite this routine conference announcement would have fit ELDN’s recent pattern of weakness around news, where offerings and even positive clinical updates on Nov 14 and Nov 18 were followed by declines. With shares already below the 200-day moving average of $2.96, further downside would have highlighted ongoing concern about financing history, execution risk, and the company’s ability to convert clinical visibility into durable shareholder support.
Key Terms
webcast technical
AI-generated analysis. Not financial advice.
IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT).
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
When will Eledon (ELDN) present at the Piper Sandler Healthcare Conference?
Who from Eledon (ELDN) will speak at the December 4, 2025 fireside chat?
How can investors watch Eledon (ELDN) at the 37th Annual Piper Sandler Healthcare Conference?
What time is Eledon's (ELDN) webcast for Pacific Time on December 4, 2025?
Will a replay of Eledon's (ELDN) Piper Sandler presentation be available after the event?
